Loading…
Loading…
MDLN (Medline Inc.) is a recent IPO.
It began trading on December 17, 2025, giving it less than a year of public history. Many charts and metrics below are sparse or empty until more price, financial, and analyst history accumulates. The affected sections are flagged individually so you can tell limited history from missing data.
MDLN does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MDLN and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MDLN and 80,000+ other tickers.
See exactly how MDLN's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDLN and 80,000+ other tickers.
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes, both domestically and worldwide. The company's operations are divided into two primary divisions: the Medline Brand and Supply Chain Solutions. The Medline Brand division focuses on the production and sourcing of its proprietary medical products, categorized into three key areas: Within Frontline Care, Medline provides a wide array of patient-facing…
NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Medline Inc. (“Medline” or the “Company”) (NASDAQ: MDLN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.
Banque Pictet and Cie SA boosted its position in shares of Medline (NASDAQ: MDLN) by 2.0% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 7,455,089 shares of the company's stock after acquiring an additional 142,939 shares during the quarter. Medline comprises about
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Medline Inc. (NASDAQ:MDLN) for potential securities fraud after its significant stock drops. If you invested in Medline securities, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/medline-class-action-lawsuit.